Published in Surgery Litigation and Law Weekly, April 20th, 2007
This trend article about University of Alberta, Canada, is an immediate alert from NewsRx to identify developing directions of research.
Study 1: Research findings, "The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells," are discussed in a new report. "The Edmonton Protocol for islet transplantation has provided hope for type 1 diabetic patients. However, this protocol requires lifelong immunosuppression, specifically sirolimus, a cellular antiproliferate," researchers in Edmonton, Canada report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Surgery Litigation and Law Weekly